Pharmanutra

Historical price data

Pharmanutra's mission is to advance nutraceutical science by developing clinically-proven, high-quality food supplements and medical devices. Its key achievement is building a defensible commercial portfolio anchored by its patented Sucrosomial® and Esteri Cetilici delivery technologies, which are supported by a growing body of peer-reviewed research. The company's strategy focuses on generating robust clinical data to differentiate its products, expanding its international footprint from its strong Italian base, and leveraging its R&D pipeline to address nutritional deficiencies and functional support across multiple therapeutic areas. Pharmanutra's public listing provides capital for this focused growth strategy.

Patented delivery systems, primarily Sucrosomial® Technology (a phospholipid-sucrose ester matrix for enhanced mineral bioavailability) and Esteri Cetilici (cetylated fatty acids for joint and muscle support), form the core technological moat.

Pharmanutra competes against mass-market supplement brands on scientific differentiation and against pharmaceutical companies on agility and specialized technology. Its primary competitive advantage is its patented delivery platforms (Sucrosomial®, Esteri Cetilici), which are defended by IP and supported by peer-reviewed clinical data, creating a moat in the high-value, medical-channel nutraceutical segment.